Understanding the immune profile associated with the premalignant lesions of Lynch syndrome may open the door to the development of preventive vaccines for the disorder, according to a whole genome transcriptomic analysis of colorectal polyps and carcinomas in patients with Lynch syndrome.
- The genetic analysis was performed on 28 polyps and 3 early stage Lynch syndrome colorectal tumors in 24 patients with Lynch syndrome and familial adenomatous polyposis.
- Lynch syndrome polyps had a unique immune activation profile that included CD4 T cells, tumor necrosis factor and interleukin 12 molecules, as well as checkpoint molecules, including lymphocyte activation gene 3 and programmed cell death 1 ligand 1.
- The findings suggest that immune checkpoint inhibitors and preventive vaccines may help combat Lynch syndrome.
Chang K, Taggart MW, Reyes-Uribe L, et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. [Published online ahead of print April 16, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.1482.
This Week's Must Reads
Must Reads in Vaccines
Vaccination for Prevention of Herpes Zoster, Ann Intern Med; ePub 2019 Feb 19; Prosser, et al